Treatment of Patients With COVID-19 With Convalescent Plasma

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

convalescent plasma

The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Trial Locations (1)

01403-002

University of Sao Paulo - General Hospital, São Paulo

All Listed Sponsors
collaborator

Ministério da Ciência, Tecnologia, Inovações e Comunicações

UNKNOWN

collaborator

Faculty of Medicine of Ribeirão Preto (FMRP-USP)

OTHER

collaborator

Hospital de Clínicas, Faculdade de Medicina Universidade Estadual de Campinas

UNKNOWN

collaborator

Hospital Sirio-Libanes

OTHER

collaborator

Hospital Israelita Albert Einstein

OTHER

collaborator

Grupo Hospitalar Conceição

OTHER_GOV

collaborator

Hospital Ernesto Dornelles

OTHER

lead

University of Sao Paulo General Hospital

OTHER

NCT04415086 - Treatment of Patients With COVID-19 With Convalescent Plasma | Biotech Hunter | Biotech Hunter